Overview A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC) Status: Recruiting Trial end date: 2022-09-01 Target enrollment: Participant gender: Summary This study will evaluate the efficacy and safety of CBP-307 in subjects with moderate to severe ulcerative colitis (UC). Phase: Phase 2 Details Lead Sponsor: Suzhou Connect Biopharmaceuticals, Ltd.